SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.99% Stake in Palisade Bio, Inc.

Armistice Capital, LLC and Steven Boyd have disclosed a 9.99% beneficial ownership stake in Palisade Bio, Inc. as of December 31, 2024, through an amended Schedule 13G filing.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Palisade Bio, Inc.
• As of December 31, 2024, the Reporting Persons collectively beneficially own 285,417 shares of Palisade Bio, Inc. Common Stock.
• This ownership represents 9.99% of the outstanding class of securities.
• Armistice Capital, LLC, a Delaware entity, is an investment adviser, and Steven Boyd, a U.S. citizen, is its managing member.
• The shares are held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company, for which Armistice Capital, LLC acts as the investment manager, exercising shared voting and dispositive power over the securities.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in tone. However, the disclosure of a significant stake (9.99%) by an institutional investor like Armistice Capital can be interpreted as a moderately positive signal of confidence in the issuer, Palisade Bio, Inc.

Positives

• The disclosure of a significant stake (9.99%) by an institutional investor like Armistice Capital and its managing member, Steven Boyd, may signal confidence in Palisade Bio, Inc.
• The filing indicates a passive investment intent, stating the shares were acquired and are held in the ordinary course of business and not for control purposes, which can be viewed positively by the issuer's management.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a standard disclosure of significant beneficial ownership by an institutional investor in a publicly traded company. It does not provide specific insights into broader industry trends but reflects an investment decision within the biotechnology or pharmaceutical sector, where Palisade Bio, Inc. operates.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant institutional holder, which can influence investor perception and potentially share price.

Key Dates

Keywords

Palisade Bio, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Biotechnology, Healthcare